; and (B) shall not be collected for any fiscal year except to the extent provided in advance in appropriation Acts. (d) Notice of Issuance of Voucher and Approval of Products Under Voucher The Secretary shall publish a notice in the Federal Register and on the Internet website of the Food and Drug Administration not later than 30 calendar days after the occurrence of each of the following: (1) The Secretary issues a priority review voucher under this section. (2) The Secretary approves a drug pursuant to an application submitted under section 505(b) of this Act or section 351(a) of the Public Health Service Act for which the sponsor of the application used a priority review voucher issued under this section. (e) Eligibility for Other Programs Nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this Act, except that no sponsor of a material threat medical countermeasure application may receive more than one priority review voucher issued under any section of this Act with respect to such drug. (f) Relation to Other Provisions The provisions of this section shall supplement, not supplant, any other provisions of this Act or the Public Health Service Act that encourage the development of medical countermeasures. (g) Sunset The Secretary may not award any priority review vouchers under subsection (b) after October 1, 2024. . 8. Including antifungal products in the CARB–X program (a) In general The Secretary of Health and Human Services shall, in carrying out the Combating Antibiotic Resistant Bacteria Accelerator program of the Department of Health and Human Services (commonly referred to as CARB–X ), conduct research with respect to antifungal resistance, including therapies, diagnostics, and vaccines, including for coccidioidomycosis. (b) Authorization of appropriations There are authorized to be appropriated to the Biodefense Medical Countermeasure Development Fund established under section 319L(d) of